Thrombosis / 2013 / Article / Tab 2 / Review Article
Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups Table 2 Characteristics of the patients and events (overall study population).
Drug, trial Dabigatran RE-LY [22 , 48 ]
Rivaroxaban ROCKET [23 , 49 ] Apixaban ARISTOTLE [24 , 50 ]
-value*No in sample 18113 14264 18201 Patients characteristics Age (years) 72 (mean) 73 (median) 70 (median) — Male gender 11514 (64%) 8604 (60%) 5660 (65%) <0.0001 CHADS2 (mean ± standard deviation)
<0.0001 CHADS2 ≥ 2 12337 (68%) 14261 (≈ 100%) 12018 (66%) <0.0001 CHADS2 = 1 5775 (32%) 3 (≈ 0%) 6183 (34%) <0.0001 Prior stroke/transient ischemic attack 3623 (20%) 7468 (55%) 3436 (19%) <0.0001 Congestive heart failure 5793 (32%) 8908 (63%) 6451 (35%) <0.0001 Hypertension 14283 (79%) 12910 (91%) 15916 (87%) <0.0001 Age ≥ 75 years 7238 (40%) 6229 (43%) 5678 (31%) <0.0001 Diabetes 4221 (23%) 5695 (40%) 4547 (25%) <0.0001 Prior myocardial infarction 3005 (17%) 2468 (17%) 2585 (14%) <0.0001 Patients in centers with TTR ≥ 65% 8950 (49%) 3493 (24%) 9046 (50%) <0.0001 Patients recruited in Europe 6770 (37%) 7582 (53%) 7343 (40%) <0.0001 Patients with CrCl < 50 mL/min 3505 (19%) 2986 (21%) 3017 (17%) <0.0001 Type of atrial fibrillation Permanent-persistent 12164 (67%) 11548 (81%) 15412 (85%) <0.0001 Paroxysmal 5943 (33%) 2514 (18%) 2786 (15%) <0.0001 Antithrombotic treatment at baseline VKA 8989 (50%) 8904 (62%) 10401 (57%) <0.0001 Acetylsalicylic acid 7198 (40%) 5205 (37%) 5632 (31%) <0.0001 Event rate in the control group
Total stroke or SEE 202 (3.35%) 306 (4.29%) 265 (2.92%) 0.0001 Ischemic stroke 143 (2.37%) 226 (3.17%) 175 (1.93%) <0.0001 Hemorrhagic stroke 45 (0.75%) 57 (0.80%) 78 (0.75%) 0.9968 SEE 16 (0.27%) 25 (0.35%) 15 (0.17%) 0.2367 Intracranial bleeding 90 (1.49%) 84 (1.18%) 122 (1.34%) 0.6421 Major bleeding 421 (6.99%) 386 (5.41%) 462 (5.09%) <0.0001 Death 487 (8.09%) 632 (8.86%) 669 (7.37%) 0.0168 Treatment discontinuation† 1150 (19%) 2468 (35%) 2732 (30%) <0.0001
Chi-square test for categorical variables and one-way analysis of variance (ANOVA) for continuous variables.† Treated patients that received assigned study drug but did not complete study.
